Mesenchymal stem cells and uses therefor
Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
1. A method of treating Acute Respiratory Diseases Syndrome (ARDS) in a patient comprising administering to the patient isolated, cultured, genetically unmanipulated mesenchymal stem cells in an amount effective to treat the ARDS.
2. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic.
3. The method of claim 1 , wherein the mesenchymal stem cells are autologous.
4. The method of claim 1 , wherein the mesenchymal stem cells are administered in a suspension comprising an acceptable pharmaceutical carrier.
5. The method of claim 1 , wherein the mesenchymal stem cells are administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.
6. The method of claim 1 , wherein the mesenchymal stem cells are administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.
7. The method of claim 1 , wherein the mesenchymal stem cells are isolated from marrow.
8. The method of claim 7 , wherein the marrow is iliac crest marrow.
9. The method of claim 1 , wherein the patient is human and the mesenchymal stem cells are human.
10. The method of claim 2 , wherein the patient is human and the mesenchymal stem cells are human.
11. The method of claim 3 , wherein the patient is human and the mesenchymal stem cells are human.
12. The method of claim 1 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.
13. The method of claim 1 , wherein the mesenchymal stem cells are administered intravenously or intraarterially.
14. The method of claim 2 , wherein the mesenchymal stem cells are administered intravenously or intraarterially.
15. The method of claim 1 , wherein ARDS is treated.
16. A method of treating chronic obstructive pulmonary disease (COPD) in a patient comprising administering to the patient isolated, cultured, genetically unmanipulated mesenchymal stem cells in an amount effective to treat the COPD.
17. The method of claim 16 , wherein COPD is treated.
18. The method of claim 16 , wherein the mesenchymal stem cells are allogeneic.
19. The method of claim 16 , wherein the mesenchymal stem cells are autologous.
20. The method of claim 16 , wherein the mesenchymal stem cells are administered in a suspension comprising an acceptable pharmaceutical carrier.
21. The method of claim 16 , wherein the mesenchymal stem cells are administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.
22. The method of claim 16 , wherein the mesenchymal stem cells are administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.
23. The method of claim 16 , wherein the mesenchymal stem cells are isolated from marrow.
24. The method of claim 23 , wherein the marrow is iliac crest marrow.
25. The method of claim 16 , wherein the patient is human and the mesenchymal stem cells are human.
26. The method of claim 18 , wherein the patient is human and the mesenchymal stem cells are human.
27. The method of claim 19 , wherein the patient is human and the mesenchymal stem cells are human.
28. The method of claim 16 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.
29. The method of claim 16 , wherein the mesenchymal stem cells are administered intravenously or intraarterially.
30. The method of claim 18 , wherein the mesenchymal stem cells are administered intravenously or intraarterially.